Dare Bioscience (DARE) Non-Current Deffered Revenue (2016 - 2025)

Dare Bioscience (DARE) has 9 years of Non-Current Deffered Revenue data on file, last reported at $1.0 million in Q3 2025.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $1.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.0 million (changed 0.0% YoY) and the FY2024 annual result came in at $1.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $1.0 million in Q3 2025, from $1.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q2 2023 to a low of $1.0 million in Q1 2021.
• A 5-year average of $1.0 million and a median of $1.0 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue increased 20.52% — and 2024, when it declined 17.03%.
• Tracing DARE's Non-Current Deffered Revenue over 5 years: stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $1.0 million (Q3 2025), $1.0 million (Q2 2025), and $1.0 million (Q1 2025), per Business Quant data.